We found that NRAS mutation was associated with poorer overall survival (OS), and TMB was predictive of dual ICI response, suggesting that tumor genetics may help serve as an informative biomarker predictive of ICI response and clinical outcomes for cutaneous melanoma. Here, NRAS is linked to neoplasm.